WEKO3
アイテム
{"_buckets": {"deposit": "d935a063-1024-4aa7-8c57-2eca3b06bdf7"}, "_deposit": {"created_by": 1, "id": "65683", "owners": [1], "pid": {"revision_id": 0, "type": "depid", "value": "65683"}, "status": "published"}, "_oai": {"id": "oai:repo.qst.go.jp:00065683", "sets": ["29"]}, "author_link": ["647031", "647041", "647032", "647042", "647033", "647039", "647040", "647035", "647038", "647044", "647030", "647036", "647037", "647043", "647034"], "item_10005_date_7": {"attribute_name": "発表年月日", "attribute_value_mlt": [{"subitem_date_issued_datetime": "2015-06-09", "subitem_date_issued_type": "Issued"}]}, "item_10005_description_5": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "64Cu-diacetyl-bis (N4-methylthiosemicarbazone) (64Cu-ATSM) is a promising theranostic agent targeting over-reduced condition under hypoxia in tumors. Clinical studies on diagnosis with radiolabeled Cu-ATSM are currently conducted worldwide, revealing its prognostic value. However, detailed characteristics of the region of high 64Cu-ATSM uptake remained unclear. Here, using human colon carcinoma HT-29 model, we investigated characteristics of 64Cu-ATSM uptake regions relating to tumor malignancy, such as up-regulation of DNA repair and concentration of CD133+ cancer stem cells, and developed a strategy to enhance 64Cu-ATSM internal radiotherapy efficacy by inhibiting DNA repair with co-administration of nucleic acid (NA) antagonists. Methods: Distribution of 64Cu-ATSM was examined in HT29 tumors, and the samples from regions identified as 64Cu-ATSM high- and low-uptake regions were used for characterization. Gene expression profile, NA incorporation (BrdU uptake), and CD133+ cell ratio were studied. For in vivo treatment study, 64Cu-ATSM (37 MBq) injection with or without co-administration of NA antagonists was tested and compared to 64Cu-ATSM alone (37 or 74 MBq). Results: Up-regulation of the pathways related to DNA repair along with BrdU uptake, and elevated CD133+ cell ratio were observed in 64Cu-ATSM high-uptake regions. In treatment study, 64Cu-ATSM showed dose-dependent inhibition of tumor growth, although 74 MBq showed significant toxicity. Co-administration of NA antagonists with 37 MBq 64Cu-ATSM showed greater tumor growth suppression than 74 MBq 64Cu-ATSM alone, without significant toxicity, and effectively reduced CD133+ cell ratio. Conclusions: 64Cu-ATSM accumulation was associated with tumor malignant characteristics and 64Cu-ATSM therapy with NA antagonists could be an effective approach to target these characteristics.", "subitem_description_type": "Abstract"}]}, "item_10005_description_6": {"attribute_name": "会議概要(会議名, 開催地, 会期, 主催者等)", "attribute_value_mlt": [{"subitem_description": "The Society of Nuclear Medicine (SNM) annual meeting 2015", "subitem_description_type": "Other"}]}, "item_access_right": {"attribute_name": "アクセス権", "attribute_value_mlt": [{"subitem_access_right": "metadata only access", "subitem_access_right_uri": "http://purl.org/coar/access_right/c_14cb"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Yoshii, Yukie"}], "nameIdentifiers": [{"nameIdentifier": "647030", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Furukawa, Takako"}], "nameIdentifiers": [{"nameIdentifier": "647031", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Matsumoto, Hiroki"}], "nameIdentifiers": [{"nameIdentifier": "647032", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yoshimoto, Mitsuyoshi"}], "nameIdentifiers": [{"nameIdentifier": "647033", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Zhang, Ming-Rong"}], "nameIdentifiers": [{"nameIdentifier": "647034", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kiyono, Yasushi"}], "nameIdentifiers": [{"nameIdentifier": "647035", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Fujibayashi, Yasuhisa"}], "nameIdentifiers": [{"nameIdentifier": "647036", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Saga, Tsuneo"}], "nameIdentifiers": [{"nameIdentifier": "647037", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "吉井 幸恵", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "647038", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "古川 高子", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "647039", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "松本 博樹", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "647040", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "吉本 光喜", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "647041", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "張 明栄", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "647042", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "藤林 康久", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "647043", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "佐賀 恒夫", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "647044", "nameIdentifierScheme": "WEKO"}]}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "conference object", "resourceuri": "http://purl.org/coar/resource_type/c_c94f"}]}, "item_title": "64Cu-ATSM internal radiotherapy targeting tumor malignant regions: sensitization based on its biological characteristics", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "64Cu-ATSM internal radiotherapy targeting tumor malignant regions: sensitization based on its biological characteristics"}]}, "item_type_id": "10005", "owner": "1", "path": ["29"], "permalink_uri": "https://repo.qst.go.jp/records/65683", "pubdate": {"attribute_name": "公開日", "attribute_value": "2015-06-18"}, "publish_date": "2015-06-18", "publish_status": "0", "recid": "65683", "relation": {}, "relation_version_is_last": true, "title": ["64Cu-ATSM internal radiotherapy targeting tumor malignant regions: sensitization based on its biological characteristics"], "weko_shared_id": -1}
64Cu-ATSM internal radiotherapy targeting tumor malignant regions: sensitization based on its biological characteristics
https://repo.qst.go.jp/records/65683
https://repo.qst.go.jp/records/65683b204dd55-c97b-42e4-9198-c54530a4ca6a
Item type | 会議発表用資料 / Presentation(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2015-06-18 | |||||
タイトル | ||||||
タイトル | 64Cu-ATSM internal radiotherapy targeting tumor malignant regions: sensitization based on its biological characteristics | |||||
言語 | ||||||
言語 | eng | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_c94f | |||||
資源タイプ | conference object | |||||
アクセス権 | ||||||
アクセス権 | metadata only access | |||||
アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
著者 |
Yoshii, Yukie
× Yoshii, Yukie× Furukawa, Takako× Matsumoto, Hiroki× Yoshimoto, Mitsuyoshi× Zhang, Ming-Rong× Kiyono, Yasushi× Fujibayashi, Yasuhisa× Saga, Tsuneo× 吉井 幸恵× 古川 高子× 松本 博樹× 吉本 光喜× 張 明栄× 藤林 康久× 佐賀 恒夫 |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | 64Cu-diacetyl-bis (N4-methylthiosemicarbazone) (64Cu-ATSM) is a promising theranostic agent targeting over-reduced condition under hypoxia in tumors. Clinical studies on diagnosis with radiolabeled Cu-ATSM are currently conducted worldwide, revealing its prognostic value. However, detailed characteristics of the region of high 64Cu-ATSM uptake remained unclear. Here, using human colon carcinoma HT-29 model, we investigated characteristics of 64Cu-ATSM uptake regions relating to tumor malignancy, such as up-regulation of DNA repair and concentration of CD133+ cancer stem cells, and developed a strategy to enhance 64Cu-ATSM internal radiotherapy efficacy by inhibiting DNA repair with co-administration of nucleic acid (NA) antagonists. Methods: Distribution of 64Cu-ATSM was examined in HT29 tumors, and the samples from regions identified as 64Cu-ATSM high- and low-uptake regions were used for characterization. Gene expression profile, NA incorporation (BrdU uptake), and CD133+ cell ratio were studied. For in vivo treatment study, 64Cu-ATSM (37 MBq) injection with or without co-administration of NA antagonists was tested and compared to 64Cu-ATSM alone (37 or 74 MBq). Results: Up-regulation of the pathways related to DNA repair along with BrdU uptake, and elevated CD133+ cell ratio were observed in 64Cu-ATSM high-uptake regions. In treatment study, 64Cu-ATSM showed dose-dependent inhibition of tumor growth, although 74 MBq showed significant toxicity. Co-administration of NA antagonists with 37 MBq 64Cu-ATSM showed greater tumor growth suppression than 74 MBq 64Cu-ATSM alone, without significant toxicity, and effectively reduced CD133+ cell ratio. Conclusions: 64Cu-ATSM accumulation was associated with tumor malignant characteristics and 64Cu-ATSM therapy with NA antagonists could be an effective approach to target these characteristics. | |||||
会議概要(会議名, 開催地, 会期, 主催者等) | ||||||
内容記述タイプ | Other | |||||
内容記述 | The Society of Nuclear Medicine (SNM) annual meeting 2015 | |||||
発表年月日 | ||||||
日付 | 2015-06-09 | |||||
日付タイプ | Issued |